Welcome to our dedicated page for American Well Corporation news (Ticker: AMWL), a resource for investors and traders seeking the latest updates and insights on American Well Corporation stock.
American Well Corporation (NYSE: AMWL), commonly known as Amwell, is a pioneering force in the telehealth industry, delivering comprehensive digital healthcare solutions both in the United States and globally. Amwell integrates providers, insurers, patients, and innovators through its state-of-the-art hybrid care enablement platform, aimed at providing greater access to more affordable and high-quality care.
Amwell’s platform supports a wide range of telehealth needs, encompassing urgent care, acute and post-acute care, behavioral health, chronic care management, and healthy living. With nearly two decades of expertise, the company powers digital care solutions for over 2,000 hospitals and 55 health plan partners, collectively reaching over 100 million covered lives.
In recent developments, Amwell has showcased impressive growth and resilience. Their third quarter of 2023 revenue totaled $61.9 million, with notable achievements such as a net loss reduction and an improved Adjusted EBITDA. The company recently secured a significant contract to support the U.S. Defense Health Agency’s Digital First initiatives, underlining the robustness and scalability of their Converge™ platform.
Another milestone was the recognition of SilverCloud®, Amwell’s digital mental health platform, with three prestigious healthcare honors. SilverCloud continues to make a significant impact in mental health support globally, offering 24/7 access to therapeutic care.
In addition, Amwell is actively pursuing innovative partnerships, such as the collaboration with Amplar Health in Australia to expand digital care and chronic disease prevention programs. This partnership emphasizes Amwell’s dedication to proactive healthcare models that leverage patient-generated data for improved outcomes.
Despite challenges, including compliance with NYSE listing standards and competitive pressures, Amwell remains committed to evolving its platform capabilities and operational efficiencies. The company’s recent Corporate Responsibility Report underscores its dedication to environmental, social, and governance (ESG) goals, highlighting meaningful progress in diverse talent representation, health equity initiatives, and cybersecurity enhancements.
For more insights into Amwell’s operations, financial performance, and upcoming events, visit their investor relations page at https://investors.amwell.com.
Amwell (NYSE: AMWL) will report its first-quarter 2023 operating results on May 3, 2023, at 5 p.m. Eastern time. Following the earnings release, the management team will host a live conference call to discuss results and provide updates.
Investors can access the live audio webcast on the Amwell Investors website or dial in at (888) 510-2008 for U.S. listeners and (646) 960-0306 internationally. The conference ID is 7830032, with a replay available for 90 days post-call.
Amwell is a leader in digital healthcare, with a platform used by over 2,000 hospitals and covering over 80 million lives. The company aims to enhance healthcare access and quality through digital solutions, supporting various care types.
DarioHealth Corp. (Nasdaq: DRIO) has entered into a strategic partnership with Amwell (NYSE: AMWL), integrating Dario's cardiometabolic solutions into Amwell's digital care delivery platform, which covers over 90 million lives. This collaboration aims to enhance the care experience for individuals with conditions such as diabetes and hypertension by providing access to Dario's personalized digital health solutions. The Dario cardiometabolic suite will be available to Amwell customers in the second half of 2023, promoting a seamless member journey and supporting better health management.
Amwell (NYSE: AMWL) has announced the launch of its new cardiometabolic program, enhancing its ecosystem of digital health solutions to better serve members with chronic diseases like diabetes and high blood pressure. This initiative, in partnership with DarioHealth (Nasdaq: DRIO), integrates Dario's personalized digital therapeutic solutions into the Amwell platform, facilitating seamless referrals for clinicians. The program aims to improve health outcomes by ensuring continuous care and engagement for over one-third of Americans living with metabolic conditions. Through connected devices and coaching, members experience a holistic approach to managing their health.
Amwell (NYSE: AMWL) reported its Q4 and full-year 2022 financial results, revealing a total revenue of $79.2 million for Q4, up 9% year-over-year. Subscription revenue reached $30.7 million, and AMG Visit revenue was $35.1 million, contributing to a gross margin of 42.4%. Although the net loss narrowed to $61.6 million from the previous quarter's $70.6 million, adjusted EBITDA remained negative at ($43.4) million. Active providers surged 11% to approximately 107,000, with total visits increasing to 1.7 million, up 10%. The company projects revenue between $275 and $285 million for 2023, reflecting ongoing growth.
Amwell (NYSE: AMWL), a leader in digital healthcare, announces CFO Robert Shepardson will participate in a fireside chat at the Cowen 43rd Annual Healthcare Conference on March 7, 2023, at 9:10 AM ET. A follow-up audio webcast will be available afterward on their investor relations page. Amwell aims to enhance digital care delivery, connecting providers, insurers, patients, and innovators to improve access to quality care. The company supports over 2,000 hospitals and 55 health plan partners, covering over 80 million lives with its comprehensive digital health solutions.
Amwell (NYSE: AMWL), a digital healthcare leader, announced it will report its fourth quarter operating results for the period ending December 31, 2022, on February 22, 2023, at 5:00 p.m. Eastern Time. Following the earnings release, the management team will host a live conference call and webcast to discuss results and provide business updates. Access to the webcast will be available on the company's investor relations website. Amwell connects healthcare providers, insurers, and patients, serving over 80 million lives through its digital care platform.
Amwell® (NYSE: AMWL) announced its third-quarter financial results for 2022, reporting a total revenue of $69.2 million, an 11% increase from $62.2 million in Q3 2021. Subscription revenue grew by 19% to $31.9 million, while AMG Visit revenue was $28.8 million. Gross margin stood at 40%. The net loss was ($70.6 million), slightly higher than the ($69.7 million) loss in Q2 2022. Active providers increased by 23% to 98,500. The company expects to meet its annual revenue guidance of $275 to $285 million and has refined its Adjusted EBITDA outlook to between ($180) million and ($190) million.